X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Takeover drama between Pfizer and AstraZeneca reached PM’s door

Yuvraj_pawp by Yuvraj_pawp
29th June 2014
in Europe, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The takeover drama of Britain’s AstraZeneca by US drugs giant Pfizer has now reached British prime minister David Cameron’s doorstep. 

In a letter to Cameron, Pfizer chief Ian C. Read tried to address concerns over the bid and said it had no plans to cut jobs or close labs in UK.

There have been worries that a takeover of AstraZeneca which employs 6700 people in UK could lead to a cut down of staff. 

On Wednesday, scientific bodies raised concerns about possible UK lab closures following a Pfizer deal. 

Pfizer however told Cameron that it would go ahead with Astra’s planned research and development base in Cambridge and retain its Macclesfield manufacturing facilities. 

Meanwhile Pfizer made a fresh offer and raised the price it is offering for Astra to £50 a share, valuing the firm at £63 billion. 

Pfizer’s initial offer in January was worth £46.61 per AstraZeneca share valued at £58.8 billion. 

Astra said the new terms offered were “inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer”. 

Cameron’s spokesperson said the UK government regards the potential takeover bid as a matter for the respective boards and shareholders of the two companies. 

“The PM has received a letter from the Chief Executive of Pfizer and today spoke to the Chairman of AstraZeneca who set out the Board’s confidence in AstraZeneca’s strategy as an independent company. The government is determined to secure great British science, research and manufacturing jobs in the life sciences sector. We want to see the sector continue to flourish and grow, with Britain retaining its scientific leadership and key R&D operations for the long-term, as well as its role as a leading manufacturing base. That is also the clear and consistent message we have given to Pfizer”. 

“The letter from the chief executive of Pfizer is a positive sign with significant undertakings on research, jobs and investment. The government will consider these proposals carefully as to whether they offer sufficient protection of our priorities. Obviously it remains unclear whether Pfizer’s takeover will actually proceed,” the spokesperson said. 

On the letter to Cameron, Read says “I am writing to you to address the concerns of the UK government and science community and your desire to have firm and enduring assurances from us about our commitment to the UK and its life sciences agenda. We believe the industrial logic for a combination between Pfizer and AstraZeneca is compelling. A combined company would bring together powerful and world leading research expertise in key therapeutic areas such as oncology, inflammation and cardiovascular and metabolic disorders, in which the world class academic research resources in the “golden triangle” of Oxford, Cambridge and London would represent a vital component”. 

He added “Pfizer commits to establishing the combined company’s corporate and tax residence in England. Pfizer commits to complete the construction of the currently planned AstraZeneca Cambridge campus, creating a substantial R&D innovation hub in Cambridge. Pfizer will base key scientific leadership in the UK who will lead all European and certain global R&D functions based in Cambridge. Pfizer commits to base the combined company’s European business HQ in the UK and commits to invite at least two AstraZeneca Board Members to join the Board of the new company”.

Tags: Europe
Previous Post

Par Pharmaceutical Statement on Brevital® Sodium

Next Post

Boehringer Ingelheim Statement on Hepatitis C drug development

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Soon, get HIV tests done at UK supermart

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In